| 29.65 1.33 (4.7%) | 05-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.36 | 1-year : | 40.48 |
| Resists | First : | 31.98 | Second : | 34.66 |
| Pivot price | 28.58 |
|||
| Supports | First : | 27.65 | Second : | 23.01 |
| MAs | MA(5) : | 28.66 |
MA(20) : | 28.83  |
| MA(100) : | 32.44 |
MA(250) : | 28.98 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 33.6 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 39.27 | Low : | 18.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IDYA ] has closed Bollinger Bands are 61.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 29.87 - 30.08 | 30.08 - 30.24 |
| Low: | 28.17 - 28.39 | 28.39 - 28.56 |
| Close: | 29.36 - 29.7 | 29.7 - 29.97 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Tue, 19 May 2026
IDYA: Lead asset shows strong efficacy in uveal melanoma; pipeline and market expansion underway - TradingView
Fri, 15 May 2026
Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA) - Stock Titan
Tue, 05 May 2026
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
Tue, 05 May 2026
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
Tue, 05 May 2026
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Tue, 05 May 2026
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 8.701e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 9,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8068e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -62.2 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 654.6 % |
| Return on Equity (ttm) | -10.8 % |
| Qtrly Rev. Growth | 2.2527e+008 % |
| Gross Profit (p.s.) | -1.1 |
| Sales Per Share | 2.48 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 11.91 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 1.171e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|